Published : Dec-2019
No. of Pages : 356
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Moderate Growth Expected in the MS Market from 2018 to 2028
2.2 R&D and Corporate Strategies Within the MS Market
2.3 Current Treatments Leave a High Level of Unmet Need in the MS Market
2.4 Opportunities Remain for Products that Fulfill Significant Unmet Needs in the MS Market
2.5 Late-Stage Pipeline Drugs Entering the MS Market Will Be a Key Driver of Growth
2.6 What Do the Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification
4.2.1 Relapsing-Remitting MS
4.2.2 Secondary Progressive MS
4.2.3 Primary Progressive MS
4.2.4 Progressive Relapsing MS
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for MS (2018-2028)
5.5.1 Diagnosed Incident Cases of MS
5.5.2 Age-Specific Diagnosed Incident Cases of MS
5.5.3 Sex-Specific Diagnosed Incident Cases of MS
5.5.4 Diagnosed Prevalent Cases of MS
5.5.5 Age-Specific Diagnosed Prevalent Cases of MS
5.5.6 Sex-Specific Diagnosed Prevalent Cases of MS
5.5.7 Diagnosed Prevalent Cases of MS by Type
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
List of Tables
Table 1: Multiple Sclerosis: Key Metrics in the Seven Major Pharmaceutical Markets
Table 2: Common Presenting Symptoms of MS
Table 3: Factors That Can Affect Prognosis in MS
Table 4: Risk Factors and Comorbid Conditions Associated with MS
Table 5: Revised 2017 McDonald Criteria for the Diagnosis of MS
Table 6: Treatment Guidelines for MS
Table 7: Top Three Disease-Modifying Therapies Prescribed for MS, by Market, 2018
Table 8: Pharmacotherapy for Common MS Symptoms
Table 9: US - MS Diagnosis Metrics
Table 10: US - MS Treatment Metrics
Table 11: France - MS Diagnosis Metrics
Table 12: France - MS Treatment Metrics
Table 13: Germany - MS Diagnosis Metrics
Table 14: Germany - MS Treatment Metrics
Table 15: Italy - MS Diagnosis Metrics
Table 16: Italy - MS Treatment Metrics
Table 17: Spain - MS Diagnosis Metrics
Table 18: Spain - MS Treatment Metrics
Table 19: UK - MS Diagnosis Metrics
Table 20: UK - MS Treatment Metrics
Table 21: Japan - MS Diagnosis Metrics
Table 22: Japan - MS Treatment Metrics
Table 23: Leading Disease-Modifying Drugs for the Treatment of MS, 2019
Table 24: Product Profile - Betaseron
Table 25: Efficacy Results for Betaseron in a Phase III (IFNBMS) Trial
Table 26: Betaseron SWOT Analysis, 2019
Table 27: Product Profile - Avonex
Table 28: Efficacy Results for Avonex in a Phase III Trial
Table 29: Avonex SWOT Analysis, 2019
Table 30: Product Profile - Rebif
Table 31: Rebif SWOT Analysis, 2019
Table 32: Product Profile - Plegridy
Table 33: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS
Table 34: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS
Table 35: AEs During Year 1 of a Phase III Trial of Plegridy in MS
Table 36: Plegridy SWOT Analysis, 2019
Table 37: Product Profile - Copaxone
Table 38: Copaxone SWOT Analysis, 2019
Table 39: Product Profile - Tysabri
Table 40: Efficacy Results for Tysabri in a Phase III (DECIDE) Trial
Table 41: Tysabri SWOT Analysis, 2019
Table 42: Product Profile - Lemtrada
Table 43: Efficacy Results for Lemtrada in a CARE II Extension Trial
Table 44: Lemtrada SWOT Analysis, 2019
Table 45: Product Profile - Ocrevus
Table 46: Efficacy Results for Ocrevus in a Phase III (OPERA I and OPERA II) MS Trial
Table 47: Efficacy Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials
Table 48: Efficacy Results for Ocrevus in Phase III (OPERA OLE) MS Trials
Table 49: Efficacy Results for Ocrevus in Phase III (ORATORIO OLE) MS Trials
Table 50: Safety Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials
Table 51: Safety Results for Ocrevus in Phase III (ORATARIO) MS Trials
Table 52: Ocrevus SWOT Analysis, 2019
Table 53: Product Profile - Gilenya
Table 54: Gilenya SWOT Analysis, 2019
Table 55: Product Profile - Aubagio
Table 56: Aubagio SWOT Analysis, 2019
Table 57: Product Profile - Tecfidera
Table 58: Tecfidera SWOT Analysis, 2019
Table 59: Product Profile - Mavenclad
Table 60: Efficacy Results for Mavenclad in a Phase III (CLARITY and CLARITY EXTENSION) MS Trial
List of Figures
Figure 1: Sales for MS by Region, 2018-2028
Figure 2: Company Portfolio Gap Analysis in MS, 2018-2028
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2018-2028
Figure 4: Accrual of Disability in the Four Subtypes of MS
Figure 5: 7MM, Diagnosed Incidence of MS (Cases per 100,000 Population), Men and Women, All Ages, 2018
Figure 6: 7MM, Diagnosed Prevalence of MS (%), Men and Women, All Ages, 2018
Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of MS
Figure 8: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS
Figure 9: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS by Type
Figure 10: 7MM, Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, N, All Ages, 2018
Figure 13: 7MM, Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
Figure 14: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
Figure 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, N, All Ages, 2018
Figure 16: 7MM, Diagnosed Prevalent Cases of MS by Type, N, Both Sexes, All Ages, 2018
Figure 17: EDSS
Figure 18: Algorithm for the Treatment of MS with DMTs
Figure 19: Overview of the Unmet Needs in MS
Figure 20: Overview of the Development Pipeline in MS
Figure 21: MS Therapeutics - Clinical Trials by Country, 2019
Figure 22: MS - Phase II-III Pipeline, 2019
Figure 23: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2018-2028
Figure 24: Company Portfolio Gap Analysis in MS, 2018-2028
Figure 25: Global Sales for MS by Region, 2018-2028
Figure 26: Global Sales for MS by Therapy Type, 2018-2028
Figure 27: Sales for MS in the US by Therapy Type, 2018-2028
Figure 28: Sales for MS in the 5EU by Therapy Type, 2018-2028
Figure 29: Sales for MS in Japan by Therapy Type, 2018-2028
